|
Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; EMD Serono; Genentech; Incyte; Merck; Pfizer; Tesaro; Xcovery |
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Xcovery |
|
|
|
|
|
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; Pfizer |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); EpicentRx (Inst); Forty Seven (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; Genentech; Lilly; Merck |
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I) |
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst) |
|
Caroline Elizabeth McCoach |
Honoraria - Genentech; Novartis |
Speakers' Bureau - Novartis |
Research Funding - Novartis; Revolution Medicines |
Travel, Accommodations, Expenses - Lilly; Loxo; Takeda |
|
|
|
|
|
|
|
|
|
|
|
Employment - Geneception; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe |
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda |
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst) |
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties |